{"entity":{"id":"paper-destiny-lung01-nejm-2022","kind":"paper","name":"DESTINY-Lung01: trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","aka":[],"tldr":"Trastuzumab deruxtecan shrank tumours in more than half of patients with previously treated HER2-mutant lung cancer, a driver with no approved therapy until this study, though lung inflammation was a serious side effect.","summary":"Phase 2 study of 91 patients with previously treated HER2-mutant metastatic non-small-cell lung cancer treated with trastuzumab deruxtecan 6.4 mg/kg.\n\nObjective response was 55 percent with median duration of response 9.3 months, median progression-free survival 8.2 months and median overall survival 17.8 months; drug-related interstitial lung disease occurred in 26 percent with two deaths.","asOf":"2026-09-17","links":[{"label":"N Engl J Med 2022","url":"https://doi.org/10.1056/NEJMoa2112431"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/34534430/"}],"tags":[],"related":[],"cancers":["her2-mutant-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab","trastuzumab-deruxtecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["destiny-lung01"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm"],"dependsOn":[],"notes":[],"journal":"New England Journal of Medicine","year":2022,"doi":"10.1056/NEJMoa2112431","pmid":"34534430","authors":"Li BT, Smit EF, Goto Y, et al.","paperType":"observational","findings":["Objective response 55 percent; median duration of response 9.3 months.","Median overall survival 17.8 months; interstitial lung disease 26 percent."],"whatItMeans":"HER2 mutations, present in about 3 percent of lung adenocarcinomas, became actionable; trastuzumab deruxtecan received the first approval for a HER2-mutant lung cancer, at the lower 5.4 mg/kg dose validated in DESTINY-Lung02.","caveats":["High rate of interstitial lung disease at 6.4 mg/kg.","Single-arm study."],"changedPractice":true,"participants":91},"route":"/key-papers/paper-destiny-lung01-nejm-2022/","neighbours":{"cancer":[{"id":"her2-mutant-nsclc","kind":"cancer","name":"HER2-mutant non-small-cell lung cancer","route":"/cancers/her2-mutant-nsclc/"}],"drug":[{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"trial":[{"id":"destiny-lung01","kind":"trial","name":"DESTINY-Lung01","route":"/trials/destiny-lung01/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}]}}